MedicalDevice Licensing.com
Innovaro Pharmalicensing
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register
About Us
Innovaro Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Pay-per-Click New!
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Innovaro Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Innovaro Pharmalicensing
is a division of
Innovaro Europe Ltd
Innovaro Corporation
Industry news

Related news

Latest News

Single Short Course of Tolerx's Otelixizumab Provides Prolonged Preservation of Beta Cell Function
Mylan Announces First-to-File Opportunity Settlement Agreements for Actoplus Met
Pacific Biomarkers, Inc. Awarded Major Research Contract As Part Of Innovative Diabetes Program
FDA Requests Additional Information Regarding AFREZZA(TM) in Complete Response Letter to MannKind
Initiation of two phase II studies with Ipsen's proprietary BIM 23A760 first-in-class chimeric compound in the treatment of acromegaly and carcinoid syndrome due to neuroendocrine tumors
NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance
Orexigen
Ipsen Grants Rhythm Exclusive Worldwide License for Two Programs in the Field of Metabolic Disorders
ACTION PHARMA REPORTS POSITIVE RESULTS IN A PROOF OF CONCEPT PHASE IB STUDY IN OBESE HUMAN VOLUNTEERS TREATED WITH SMALL MOLECULE ORAL ONCE-DAILY AP1030 TARGETED FOR TYPE II DIABETES ASSOCIATED WITH OBESITY
Transition Therapeutics Announces Licensing and Collaboration Agreement With Lilly
More news... | RSS Feed...

Most Viewed

Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity

DiaMedica announces definitive share exchange agreement with shareholders of Sanomune Inc.

ACTION PHARMA REPORTS POSITIVE RESULTS IN A PROOF OF CONCEPT PHASE IB STUDY IN OBESE HUMAN VOLUNTEERS TREATED WITH SMALL MOLECULE ORAL ONCE-DAILY AP1030 TARGETED FOR TYPE II DIABETES ASSOCIATED WITH...

FDA Accepts VIAject(R) NDA for Review

Transition Therapeutics Announces Licensing and Collaboration Agreement With Lilly

VIVUS Announces FDA Acceptance of Qnexa(R) New Drug Application for Treatment of Obesity

ReNeuron presents key pre-clinical efficacy data with ReN009 stem cell therapy at leading UK diabetes conference.

Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity

Initiation of two phase II studies with Ipsen's proprietary BIM 23A760 first-in-class chimeric compound in the treatment of acromegaly and carcinoid syndrome due to neuroendocrine tumors

Entelos Granted Patent for Innovative Diagnostic Capability in Obesity, Diabetes

Therapeutic Target

Cardiovascular
Dermatology
Endocrine and Metabolic
Gastroenterology
Genitourinary
Hematology
Immunology and Allergy
Infection
Musculoskeletal
Neurology
Obstetrics and Gynecology
Oncology
Ophthalmology
Psychiatry
Pulmonary

Categories

Deals and Alliances
Development
Financial Results
Financings
Intellectual Property
Regulatory
Press releases
Deals review
Headlines
PR Newswire

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Anglonordic VII
Press releases: Innovaro Pharmalicensing current industry press releases.

© Copyright 1998-2010 Innovaro Pharmalicensing, a division of Innovaro Europe Ltd Innovaro Corporation All rights reserved. Terms and Conditions | Contact us